Five-year Kymriah data show durable remission, long-term survival in advanced B-cell ALL

Matt Kalaycio named chair of board of directors at NCCN

Matt Kalaycio was named chair of the board of directors at the National Comprehensive Cancer Network. Christopher H. Lieu was elected as vice chair, succeeding Kalaycio in the position he has held since 2022.

April 12, 2024

Vol.50 No.15

In Brief

Christopher Hourigan named professor and director of Cancer Research Center at Virginia Tech

Christopher Hourigan, a senior investigator and chief of the Laboratory of Myeloid Malignancies at the National Institutes of Health, will join Virginia Tech as a professor with the institute and director of its Fralin Biomedical Research Institute Cancer Research Center in Washington, D.C.

April 05, 2024

Vol.50 No.14

Clinical Roundup

Novel treatment for T-cell leukemias and lymphomas demonstrates promise in preclinical study

A novel treatment for leukemias and lymphomas that arise from immune system T cells, developed by investigators at the Johns Hopkins Kimmel Cancer Center and its Ludwig Center and Lustgarten Laboratory, was found to be effective at killing these cancers in mice bearing human T-cell tumors.

April 05, 2024

Vol.50 No.14

Drugs & Targets

Ipsen and Sutro Biopharma form global licensing deal for an ADC targeting solid tumors

Ipsen and Sutro Biopharma formed an exclusive global licensing agreement for STRO-003, an antibody-drug conjugate in the final stages of preclinical development which targets the ROR1 tumor antigen which is known to be overexpressed in many different cancer types including solid tumors and hematological malignancies.

April 05, 2024

Vol.50 No.14

Regulatory News

Exercising new powers, FDA issues Complete Response Letters based on insufficient enrollment in confirmatory trials

FDA issued Complete Response Letters for the Biologics License Application for odronextamab in relapsed/refractory follicular lymphoma and in R/R diffuse large B-cell lymphoma, each after two or more lines of systemic therapy.

UF Health Proton Therapy Institute adds interactive video wall for pediatric patients

The UF Health Proton Therapy Institute enhanced its playroom, a respite for its pediatric patients, significantly with innovative technology that promotes therapeutic engagement, with an 86” interactive gaming wall that features educational and sensory software.

March 29, 2024

Vol.50 No.13

Five-year Kymriah data show durable remission, long-term survival in advanced B-cell ALL

YOU MAY BE INTERESTED IN

Matt Kalaycio named chair of board of directors at NCCN

Christopher Hourigan named professor and director of Cancer Research Center at Virginia Tech

Novel treatment for T-cell leukemias and lymphomas demonstrates promise in preclinical study

Ipsen and Sutro Biopharma form global licensing deal for an ADC targeting solid tumors

Exercising new powers, FDA issues Complete Response Letters based on insufficient enrollment in confirmatory trials

UF Health Proton Therapy Institute adds interactive video wall for pediatric patients

Renew today!

Subscriber content

Login